Nivolumab-CTnivolumabgemcitabine-cisplatinpembrolizumabEV-Pembrolizumabenfortumab vedotingemcitabineurothelial carcinomaEuropean Medicines AgencyUC
…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…